Helena Xicoy
Overview
Explore the profile of Helena Xicoy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laguna A, Penuelas N, Gonzalez-Sepulveda M, Nicolau A, Arthaud S, Guillard-Sirieix C, et al.
Nat Commun
. 2024 Oct;
15(1):8819.
PMID: 39394193
One key limitation in developing effective treatments for neurodegenerative diseases is the lack of models accurately mimicking the complex physiopathology of the human disease. Humans accumulate with age the pigment...
2.
Laguna A, Xicoy H, Tolosa E, Serradell M, Vilas D, Gaig C, et al.
NPJ Parkinsons Dis
. 2021 May;
7(1):40.
PMID: 33986284
Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson's disease (PD)) or...
3.
Xicoy H, Klemann C, De Witte W, Martens M, Martens G, Poelmans G
NPJ Parkinsons Dis
. 2021 Mar;
7(1):23.
PMID: 33674605
Parkinson's disease (PD) is characterized by the degeneration of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies. The mechanisms underlying these molecular and cellular effects are...
4.
Fang Q, Xicoy H, Shen J, Luchetti S, Dai D, Zhou P, et al.
Brain Behav Immun
. 2020 Nov;
92:127-138.
PMID: 33249171
Growing evidence indicates that microglia activation and a neuroinflammatory trigger contribute to dopaminergic cell loss in Parkinson's disease (PD). Furthermore, increased density of histaminergic fibers and enhanced histamine levels have...
5.
Xicoy H, Brouwers J, Wieringa B, Martens G
Cells
. 2020 Aug;
9(9).
PMID: 32858884
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons from the substantia nigra (SN) that project to the dorsal striatum (caudate-putamen). To better understand the molecular mechanisms underlying...
6.
Gonzalez-Sepulveda M, Laguna A, Carballo-Carbajal I, Galiano-Landeira J, Romero-Gimenez J, Cuadros T, et al.
ACS Chem Neurosci
. 2020 Aug;
11(17):2679-2687.
PMID: 32786306
Dopamine is a key neurotransmitter in the pathophysiology of various neurological disorders such as addiction or Parkinson's disease. Disturbances in its metabolism could lead to dopamine accumulation in the cytoplasm...
7.
Baekelandt V, Lobbestael E, Xicoy H, Martens G
Front Neurosci
. 2020 Apr;
14:250.
PMID: 32265647
No abstract available.
8.
Xicoy H, Penuelas N, Vila M, Laguna A
Cells
. 2019 Nov;
8(11).
PMID: 31731485
Parkinson's disease (PD) is a neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, for which no disease-modifying treatments exist. This lack of effective...
9.
Xicoy H, Brouwers J, Kalnytska O, Wieringa B, Martens G
Mol Neurobiol
. 2019 Sep;
57(2):848-859.
PMID: 31493240
Parkinson's disease (PD) is a highly prevalent neurodegenerative disease for which no disease-modifying treatments are available, mainly because knowledge about its pathogenic mechanism is still incomplete. Recently, a key role...
10.
Xicoy H, Wieringa B, Martens G
Cells
. 2019 Jan;
8(1).
PMID: 30621069
Parkinson's disease (PD) is a neurodegenerative disease characterized by a progressive loss of dopaminergic neurons from the nigrostriatal pathway, formation of Lewy bodies, and microgliosis. During the past decades multiple...